Literature DB >> 7286047

Disposition of cefoxitin in patients with ascites.

M J Garcia, A Dominguez-Gil, F D Perez, F P Rodriguez, F D Moronta.   

Abstract

The pharmacokinetics of Cefoxitin was studied in 8 cirrhotic patients with ascites after i.v. administration of a single 30 mg/kg dose. Concentrations of cefoxitin in serum and in ascitic fluid were determined simultaneously and by a microbiologic plate diffusion method. The antibiotic followed a two-compartment open kinetic model. In ascitic fluid, Cefoxitin reached its maximum concentration of 32.80 +/- 13,78 micrograms/ml 2 h after administration. The mean elimination constant from ascitic fluid was 0.201 +/- 0.008 h(-1), significantly lower (p less than 0.05) than the slow disposition phase constant (beta = 0.556 +/- 0.17 h(-1)). At the dose studied and with a dosage interval of 8 h, the level of antibiotic in the ascitic fluid would be maintained at a value greater than the MIC of most cefoxitin-sensitive organisms.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7286047     DOI: 10.1007/BF00615407

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Antibiotic penetrance of ascitic fluid in dogs.

Authors:  D N Gerding; J P Kromhout; J J Sullivan; W H Hall
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

2.  Kinetics of tissue penetration. Are high plasma peak concentrations or sustained levels preferable for effective antibiotic therapy?

Authors:  T Bergan
Journal:  Scand J Infect Dis Suppl       Date:  1978

3.  Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency.

Authors:  G Humbert; J P Fillastre; A Leroy; M Godin; C Van Winzum
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb

4.  Prediction of the concentration of penicillins in ascitic fluid from serum kinetics and protein binding of the antibiotics in serum and ascitic fluid of dogs.

Authors:  D N Gerding; L R Peterson; J K Salomonson; W H Hall; E A Schierl
Journal:  J Infect Dis       Date:  1978-08       Impact factor: 5.226

5.  The passage of cephalothin into and out of ascitic fluid.

Authors:  D E Wilson; T C Chalmers; M A Madoff
Journal:  Am J Med Sci       Date:  1967-04       Impact factor: 2.378

6.  Antibiotic concentrations in ascitic fluid of patients with ascites and bacterial peritonitis.

Authors:  D N Gerding; W H Hall; E A Schierl
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

7.  Pharmacokinetics of cefoxitin in patients undergoing hemodialysis.

Authors:  M J Garcia; A Dominguez-Gil; J M Tabernero; A Bondia Román
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-08

8.  Pharmacokinetics of cefoxitin in patients with normal or impaired renal function.

Authors:  M J Garcia; A Dominguez-Gil; J M Tabernero; J A Sanchez Tomero
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  The influence of ascites on the pharmacokinetics of amikacin.

Authors:  J M Lanao; A Dominguez-Gil; J G Macias; J L Diez; M J Nieto
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980

10.  Altered gentamicin distribution in ascitic patients.

Authors:  M A Gill; J W Kern
Journal:  Am J Hosp Pharm       Date:  1979-12
View more
  3 in total

1.  Distribution of ceftazidime in ascitic fluid.

Authors:  G Benoni; E Arosio; M G Raimondi; E Apolloni; E Passarella; A Lechi; G P Velo
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

2.  Pharmacokinetics of cefoxitin administered by i.v. infusion to patients with a pleural effusion.

Authors:  M J Otero; M J Garcia; M Barrueco; A Dominguez-Gil; F Gomez; J Portugal Alvarez
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of newer antibacterial agents in liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.